US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

SPRY

ARS Pharmaceuticals (SPRY)

ARS Pharmaceuticals Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SPRY

Fecha	Hora	Fuente	Título	Símbolo	Compañía
16/05/2024	18:52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SPRY	ARS Pharmaceuticals Inc
10/05/2024	06:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SPRY	ARS Pharmaceuticals Inc
09/05/2024	15:05	GlobeNewswire Inc.	ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results	NASDAQ:SPRY	ARS Pharmaceuticals Inc
30/04/2024	08:01	GlobeNewswire Inc.	ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand	NASDAQ:SPRY	ARS Pharmaceuticals Inc
03/04/2024	08:01	GlobeNewswire Inc.	ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)	NASDAQ:SPRY	ARS Pharmaceuticals Inc
21/03/2024	15:05	GlobeNewswire Inc.	ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:SPRY	ARS Pharmaceuticals Inc
07/03/2024	15:05	GlobeNewswire Inc.	ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day	NASDAQ:SPRY	ARS Pharmaceuticals Inc
06/03/2024	08:01	GlobeNewswire Inc.	ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024	NASDAQ:SPRY	ARS Pharmaceuticals Inc
26/02/2024	11:08	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:SPRY	ARS Pharmaceuticals Inc
26/02/2024	08:01	GlobeNewswire Inc.	ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	NASDAQ:SPRY	ARS Pharmaceuticals Inc
22/02/2024	08:01	GlobeNewswire Inc.	ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024	NASDAQ:SPRY	ARS Pharmaceuticals Inc
20/02/2024	08:01	GlobeNewswire Inc.	ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter	NASDAQ:SPRY	ARS Pharmaceuticals Inc
05/02/2024	08:01	GlobeNewswire Inc.	ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting	NASDAQ:SPRY	ARS Pharmaceuticals Inc
09/11/2023	15:00	GlobeNewswire Inc.	ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates	NASDAQ:SPRY	ARS Pharmaceuticals Inc
09/11/2023	10:02	GlobeNewswire Inc.	ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis	NASDAQ:SPRY	ARS Pharmaceuticals Inc
06/10/2023	08:57	Dow Jones News	ARS Pharmaceuticals to Meet With FDA on Neffy Rejection	NASDAQ:SPRY	ARS Pharmaceuticals Inc
06/10/2023	08:03	GlobeNewswire Inc.	ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)	NASDAQ:SPRY	ARS Pharmaceuticals Inc
03/10/2023	08:03	GlobeNewswire Inc.	Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology	NASDAQ:SPRY	ARS Pharmaceuticals Inc
20/09/2023	09:20	Dow Jones News	ARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy Setback	NASDAQ:SPRY	ARS Pharmaceuticals Inc
20/09/2023	05:30	Dow Jones News	ARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy Spray	NASDAQ:SPRY	ARS Pharmaceuticals Inc
19/09/2023	21:49	GlobeNewswire Inc.	FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study	NASDAQ:SPRY	ARS Pharmaceuticals Inc
01/09/2023	15:15	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:SPRY	ARS Pharmaceuticals Inc
10/08/2023	15:08	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SPRY	ARS Pharmaceuticals Inc
10/08/2023	15:00	GlobeNewswire Inc.	ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates	NASDAQ:SPRY	ARS Pharmaceuticals Inc
28/06/2023	15:32	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SPRY	ARS Pharmaceuticals Inc
20/06/2023	07:00	GlobeNewswire Inc.	ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis	NASDAQ:SPRY	ARS Pharmaceuticals Inc
15/05/2023	08:08	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:SPRY	ARS Pharmaceuticals Inc
15/05/2023	08:00	GlobeNewswire Inc.	ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results	NASDAQ:SPRY	ARS Pharmaceuticals Inc
12/05/2023	07:55	Dow Jones News	ARS Pharmaceuticals Soar 68% in Premarket Trading as FDA Panel Backs Neffy	NASDAQ:SPRY	ARS Pharmaceuticals Inc
11/05/2023	18:01	GlobeNewswire Inc.	FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis	NASDAQ:SPRY	ARS Pharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:SPRY

Korea District Heating

Vontobel Financial Produ...

AMUNDI PR1E INAV

UBS Lux Fund Solutions B...

SG Issuer Societe Generale

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones